Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:chemical_compound |
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:alternativeName |
gptkb:Semaxanib
3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one-5-sulfonamide |
| gptkbp:CASNumber |
286911-33-5
|
| gptkbp:developedBy |
anti-cancer agent
|
| gptkbp:has_clinical_trial_status |
discontinued
|
| gptkbp:hasMolecularFormula |
C18H19N3O3S
|
| gptkbp:hasUNII |
6QX8QG8E9K
|
| https://www.w3.org/2000/01/rdf-schema#label |
SU5419
|
| gptkbp:IUPACName |
3-[(2,4-dimethyl-1H-pyrrol-5-yl)methylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide
|
| gptkbp:mechanismOfAction |
inhibits VEGF receptor tyrosine kinases
|
| gptkbp:PubChem_CID |
5311297
CHEMBL479 |
| gptkbp:target |
gptkb:VEGFR-2
|
| gptkbp:was_investigated_for |
treatment of non-small cell lung cancer
treatment of glioblastoma treatment of renal cell carcinoma treatment of solid tumors |
| gptkbp:bfsParent |
gptkb:Upham,_Hampshire,_England
gptkb:Ashton,_Hampshire |
| gptkbp:bfsLayer |
7
|